Executive Summary
An optimized media selection and feed strategy is foundational to de-risking large-scale AAV manufacturing for next-generation therapeutics. Moving from inconsistent, serum-dependent processes to chemically defined, GxP-compliant media is a requirement for achieving the lot-to-lot consistency demanded by global regulatory bodies. A data-driven approach to upstream process development directly impacts final vector quality, titer, and the timeline for generating material sufficient for IND-enabling toxicology studies. This process directly supports the 18-24 month timeline to IND that our scientific leadership has consistently achieved.
Frequently Asked Questions
Q: How does media selection impact AAV scalable suspension processes and timelines for IND submission?
Media selection is a primary determinant of process robustness in AAV scalable suspension systems. Utilizing a chemically defined medium from an early stage minimizes process variability, simplifies supply chain logistics, and reduces the risk of introducing adventitious agents. This consistency is vital for generating reproducible data packages for multi-jurisdictional IND and IMPD submissions under ICH guidelines.
Q: What is the primary risk of using a non-optimized feed strategy when producing vector for IND-enabling toxicology studies?
A suboptimal feed strategy can lead to inconsistent vector quality attributes, including variable capsid content (%full) and lower infectious titers. This variability compromises the integrity of IND-enabling toxicology studies, as the material used may not be representative of the final clinical product. It introduces unnecessary risk into the program and can trigger regulatory delays.
Q: Can a process developed for a common serotype like AAV9 be directly applied to a novel engineered capsid?
While platform processes for established serotypes like AAV8 and AAV9 provide a strong starting point, they cannot be directly applied without modification. Each novel or engineered capsid possesses a unique isoelectric point and surface charge profile that necessitates tailored optimization of both upstream media conditions and downstream purification protocols to ensure maximum yield and purity.
A scalable upstream manufacturing process for AAV vectors depends on a media and feed strategy developed from empirical, process-specific data. The transition from small-scale, adherent culture production to large-volume suspension bioreactors introduces significant variables that can affect vector yield and quality attributes.
The selection of production media is one of the most consequential decisions in the process development lifecycle. While serum-supplemented media may suffice for initial research, its inherent lot-to-lot variability and potential for contamination present considerable risks for programs targeting clinical evaluation. Franklin Biolabs focuses on developing and optimizing chemically defined media formulations that ensure process stability and regulatory alignment for global submissions.
Data-Driven Feed Strategy Development
A robust feed strategy is designed to sustain high-density cell cultures and maximize volumetric productivity without compromising vector integrity. This involves a systematic evaluation of metabolic parameters to determine the optimal timing and composition of nutrient feeds.
This methodical approach to upstream process development ensures that the vector produced for pivotal nonclinical studies is manufactured under conditions representative of the intended GxP process. This consistency is a core component of our team’s track record, which includes a 100% successful IND rate since 2019, achieved by the core scientific leadership and principal scientists who now form Franklin Biolabs following its formal launch in 2024.
Impact on Downstream Processing and In Vivo Expression
Upstream decisions have direct consequences for downstream purification and in vivo performance. A well-controlled upstream process using optimized media reduces the burden on downstream purification steps by minimizing host cell protein and DNA contamination (PMID: 26605372). This results in a cleaner product profile and more efficient purification schemes.
A consistent manufacturing process enables predictable in vivo expression in preclinical models. The ability to reliably quantify protein expression in nonhuman primate models, for example, is predicated on a vector product with consistent quality attributes from batch to batch (PMID: 37891254). This principle of process control is foundational to the work conducted by our team within a >100,000 sq ft facility, including in past collaborations with partners like our partners.
Our integrated expertise in vector production and analytics provides partners with the well-characterized, high-quality material necessary to de-risk and accelerate their therapeutic programs.
This rigorous approach to process development is central to our ability to support sponsors moving from research to clinical manufacturing.
Learn more about our comprehensive services at our parent hub page: Large-Scale AAV Manufacturing and Process Development.
Featured Video: MAKING LIFE-SAVING RESEARCH AFFORDABLE
This video highlights how process optimization and manufacturing efficiency can reduce preclinical development timelines and costs.
Watch Video Clip
